The president and CEO of the pharmaceutical company: “New mrNa drugs coming at the end of next year”. To combat the new variants, he said “we will need new vaccines to be produced quickly.” On monoclonals: “In negotiation with AIFA for emergency approval, the drug is already in production in Italy”
“We are working with CureVac on the next generation of mrNa vaccines, which are needed to combat the variants. They will be available in late 2022.” So Fabio Landazabal, president and CEO of GlaxoSmithKline, a pharmaceutical company at the forefront of the production of monoclonals and vaccines, at Sky TG24. The CEO of GSK, who also has factories in Tuscany, adds: “The priority now is to cover the majority of the world‘s population. A new phase of development will follow to consolidate the primary vaccinations done to date. Let’s move on with the study. on protein vaccines and mrNa “.
The CureVac vaccine
read also
Covid, the German CureVac vaccine is only 47% effective
Europe has focused heavily on the production of the German vaccine CureVac, which should have been the third mrNa vaccine to become available, after those from Pfizer and Moderna. In recent days, however, the same company has spoken of a preliminary efficacy of 47% against the disease. Landazabal: “The studies are providing us with interesting data. Most of the patients on which clinical analyzes are being carried out are in Latin America, where the variants are widespread. The vaccine was effective against the Wuhan strain, but its strength decreases. against new variants. We are adapting it to a new reality. “
The impact of variants
read also
Covid, Delta variant: new pads are coming to recognize it
“When the virus changes, so does the symptomatology. This has an impact on the effectiveness of the drugs. We know that we will need new vaccines to adapt to the new reality. This is our focus: adapting the drugs to the picture we are facing and create a new generation of vaccines, which we will have to develop at a very high speed. Ours will be effective against the Delta variant, “Landazabal said.
Monoclonal drugs
read also
Aids, a monoclonal antibody can prevent infection in monkeys
A further weapon to counter the spread of variants can also be the development of drugs with monoclonal antibodies. Landazabal: “Our monoclonal was designed to join the virus’s spine. It has proved highly effective against all variants, with an 85% reduction in the risk of hospitalizations and deaths.” Regarding the timing, the CEO of GSK said that “the drug is already available, it is produced in Italy and we are already exporting it. In these days we are talking with AIFA – the Italian Medicines Agency – for an emergency approval. , therefore faster “.
GSK’s contribution to Italian vaccines
see also
Covid vaccines, the plan for migrants and non-resident populations
GlaxoSmithKline is also part of the table of the Ministry for Economic Development to develop an Italian strategy for the production of vaccines. Landazabal explains that “GSK’s contribution is to provide the government with all our expertise. Italy’s is a great project: being part of a global network for the production and development of new therapies. We hope that our support will help achieve the expected objectives “.
Date last modified
.